PTGX Company Profile and Key Details
Protagonist Therapeutics, Inc.
PTGX Stock Price Chart
Stock Price Today
Protagonist Therapeutics, Inc. (PTGX) stock surged +2.99%, trading at $38.88 on NASDAQ, up from the previous close of $37.75. The stock opened at $37.81, fluctuating between $37.81 and $39.66 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Company Information
| Employees | 126 |
| Beta | 2.16 |
| Sales or Revenue | $60.00M |
| 5Y Sales Change% | -0.236% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) stock price is $38.88 in the last trading session. During the trading session, PTGX stock reached the peak price of $39.66 while $37.81 was the lowest point it dropped to. The percentage change in PTGX stock occurred in the recent session was 2.99% while the dollar amount for the price change in PTGX stock was $1.13.
The NASDAQ listed PTGX is part of Biotechnology industry that operates in the broader Healthcare sector. Protagonist Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Abha Bommireddi
Executive Vice President of Portfolio & Program Management
Dr. Dinesh V. Patel Ph.D.
Chief Executive Officer, Pres, Sec. & Director
Mr. Mohammad Masjedizadeh
Executive Vice President & Chief Technology Officer
Dr. David Y. Liu Ph.D.
Chief R&D Strategy Officer
Mr. Matthew M. Gosling
Executive Vice President & Gen. Counsel
Dr. Richard S. Shames
Clinical Advisor
Dr. Suneel K. Gupta Ph.D.
Chief Devel. Officer
Mr. Asif Ali
Executive Vice President & Chief Financial Officer
Mr. Mohammad Masjedizadeh Ph.D.
Executive Vice President & Chief Technical Officer
Dr. Ashok Bhandari Ph.D.
Executive Vice President & Chief Drug Discovery and Preclinical Devel. Officer
Ms. Carena Spivey
Senior Vice President of HR
Dr. Scott Eric Plevy M.D.
Executive Vice President & Therapeutic Head of Gastroenterology
Dr. Richard S. Shames M.D.
Clinical Advisor
Mr. Carter J. King
Senior Vice President of Bus. Devel.
PTGX's closing price is 60.53% higher than its 52-week low of $24.22 where as its distance from 52-week high of $48.89 is -20.48%.
Number of PTGX employees currently stands at 126.
Official Website of PTGX is: https://www.protagonist-inc.com
PTGX could be contacted at phone 510 474 0170 and can also be accessed through its website. PTGX operates from 7707 Gateway Boulevard, Newark, CA 94560-1160, United States.
PTGX stock volume for the day was 756.84K shares. The average number of PTGX shares traded daily for last 3 months was 683.73K.
The market value of PTGX currently stands at $2.32B with its latest stock price at $38.88 and 59.6M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com